OpGen (NASDAQ:OPGN) Now Covered by Analysts at StockNews.com

StockNews.com started coverage on shares of OpGen (NASDAQ:OPGN) in a research report released on Monday. The brokerage issued a sell rating on the medical research company’s stock.

OpGen Stock Performance

Shares of OPGN opened at $0.60 on Monday. OpGen has a twelve month low of $0.17 and a twelve month high of $3.84. The firm’s 50 day moving average price is $0.56 and its two-hundred day moving average price is $0.51. The firm has a market cap of $7.55 million, a P/E ratio of -0.09 and a beta of -0.71.

About OpGen

OpGen, Inc, a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits.